Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 6/24/2025

ACE Inhibitors and NT-proBNP Levels in Heart Failure

Introduction to ACE and NT-proBNP Relationship

  • High ACE levels are inversely related to NT-proBNP levels, as ACE inhibition therapy leads to reduction in NT-proBNP levels in patients with heart failure, according to the American Heart Association 1
  • ACE plays a key role in the renin-angiotensin-aldosterone system (RAAS), which affects cardiac function and blood pressure, as stated by the American College of Cardiology 1
  • When ACE is inhibited through medications (ACE inhibitors), NT-proBNP levels decrease significantly, which is supported by the European Society of Cardiology 1

Effects of ACE Inhibitors on NT-proBNP Levels

  • Long-term treatment with ACE inhibitors leads to reduction in blood natriuretic peptide levels, as recommended by the American Heart Association 1
  • Higher doses of ACE inhibitors are associated with greater reductions in NT-proBNP levels, according to the European Society of Cardiology 2
  • The decrease in NT-proBNP is associated with reduction in filling pressures and reversal of pathological cardiac remodeling, as stated by the American College of Cardiology 1

Monitoring Response to ACE Inhibitor Therapy

  • NT-proBNP levels can be used to monitor response to ACE inhibitor therapy, as suggested by the American Heart Association, with a reduction >30% in NT-proBNP in response to heart failure treatment indicating good prognosis 3
  • Serial measurements of NT-proBNP can help assess treatment efficacy of ACE inhibitors and other heart failure medications, according to the European Society of Cardiology 3

Factors Affecting NT-proBNP Levels

  • NT-proBNP levels are affected by multiple factors beyond ACE activity, including age and sex (higher thresholds needed for older patients), renal dysfunction (higher levels with decreased renal function), and obesity (associated with lower NT-proBNP levels), as stated by the American College of Cardiology 1
  • Age and sex-specific cutoffs should be used when applicable, as recommended by the American Heart Association 3

Comparison of ACE Inhibitors and Other Therapies

  • Sacubitril/valsartan (ARNI) is superior to traditional ACE inhibitors in reducing NT-proBNP levels, according to the European Society of Cardiology 3
  • For patients with elevated NT-proBNP levels, treatment with ACE inhibitors should be considered as part of guideline-directed medical therapy, as suggested by the American College of Cardiology 3